This announcement is a separate document:
复星医药监事会关于2022年限制性A股激励计划首次授予所涉A股限制性股票第一期解除限售相关事项的核查意见
Fosun Pharmaceuticals Supervisory Board\'s inspection opinions on matters relating to the lifting of sales restrictions for the first phase of A-share restricted shares involved in the first phase of the 2022 restricted A-share incentive plan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.